Free Trial

TransCode Therapeutics (RNAZ) News Today

TransCode Therapeutics logo
$3.52 +0.17 (+5.07%)
As of 04:00 PM Eastern
Transcode announces SRC approved third cohort in TTX-MC138 clinical trial
TransCode Therapeutics Raises $8M in Private Placement
Transcode Therapeutics issues 21.2M shares at 37.7c in private placement
TransCode Announces 1-for-33 Reverse Stock Split
Transcode Therapeutics Reports Increased Losses Amid Funding Challenges
Transcode Therapeutics sends open letter to shareholders
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
Biotechnology (Industry) (^YH20610010)
TransCode Therapeutics Open Letter to Shareholders
Get TransCode Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter.

RNAZ Media Mentions By Week

RNAZ Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RNAZ
News Sentiment

0.00

0.63

Average
Medical
News Sentiment

RNAZ News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RNAZ Articles
This Week

0

1

RNAZ Articles
Average Week

Get TransCode Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:RNAZ) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners